EASY BIOInc Balance Sheet Health
Financial Health criteria checks 4/6
EASY BIOInc has a total shareholder equity of ₩71.8B and total debt of ₩200.0B, which brings its debt-to-equity ratio to 278.6%. Its total assets and total liabilities are ₩317.2B and ₩245.4B respectively. EASY BIOInc's EBIT is ₩28.6B making its interest coverage ratio 6.3. It has cash and short-term investments of ₩48.6B.
Key information
278.6%
Debt to equity ratio
₩200.03b
Debt
| Interest coverage ratio | 6.3x |
| Cash | ₩48.58b |
| Equity | ₩71.81b |
| Total liabilities | ₩245.38b |
| Total assets | ₩317.19b |
Recent financial health updates
Does EASY BIOInc (KOSDAQ:353810) Have A Healthy Balance Sheet?
Dec 11
We Think EASY BIOInc (KOSDAQ:353810) Can Stay On Top Of Its Debt
Aug 07Recent updates
EASY BIO,Inc.'s (KOSDAQ:353810) Share Price Boosted 27% But Its Business Prospects Need A Lift Too
Dec 17Does EASY BIOInc (KOSDAQ:353810) Have A Healthy Balance Sheet?
Dec 11EASY BIOInc (KOSDAQ:353810) Might Be Having Difficulty Using Its Capital Effectively
Nov 20We Think EASY BIOInc (KOSDAQ:353810) Can Stay On Top Of Its Debt
Aug 07Statutory Profit Doesn't Reflect How Good EASY BIOInc's (KOSDAQ:353810) Earnings Are
Mar 28Financial Position Analysis
Short Term Liabilities: A353810's short term assets (₩193.3B) exceed its short term liabilities (₩106.3B).
Long Term Liabilities: A353810's short term assets (₩193.3B) exceed its long term liabilities (₩139.1B).
Debt to Equity History and Analysis
Debt Level: A353810's net debt to equity ratio (210.9%) is considered high.
Reducing Debt: Insufficient data to determine if A353810's debt to equity ratio has reduced over the past 5 years.
Debt Coverage: A353810's debt is well covered by operating cash flow (24.4%).
Interest Coverage: A353810's interest payments on its debt are well covered by EBIT (6.3x coverage).
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 06:53 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
EASY BIO,Inc. is covered by 4 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Yu-jung Han | Daishin Securities Co. Ltd. |
| Jun-Seo Heo | Eugene Investment & Securities Co Ltd. |
| Eui-Seob Shim | NH Investment & Securities Co., Ltd. |